Engaging Opportunities Ahead: Oryzon's Upcoming Events
Oryzon Genomics' Upcoming Engagements
Oryzon Genomics, S.A. is set to make waves in the biopharmaceutical arena with its active participation in several high-profile events this November. Known for its pioneering work in epigenetics, the company’s leadership is eager to engage with stakeholders during these conferences.
Major Conferences on the Horizon
Oryzon will showcase its developments at multiple venues, presenting an excellent opportunity for networking and collaboration. One of the notable events is BIO-EUROPE, occurring from November 3-5. This prestigious event, held at the Vienna Congress and Convention Center, will gather industry leaders, facilitating discussions on innovations and trends.
LSX Investival Showcase
Following that, the LSX Investival Showcase Europe 2025 on November 17 will be another key occasion. This gathering at Old Billingsgate in London will concentrate on investment opportunities within the life sciences sector. Oryzon looks forward to sharing insights into its strategic approach and future plans.
Jefferies Global Healthcare Conference
Additionally, the Jefferies Global Healthcare Conference spans from November 17-20 at the Waldorf Hilton in London. This event is a significant platform for Oryzon to discuss its ongoing projects, connect with potential investors, and deepen existing relationships within the healthcare community.
Oryzon Genomics Overview
Established in 2000 in Barcelona, Oryzon Genomics has positioned itself as a clinical-stage biopharmaceutical leader in the field of epigenetics. The company stands out for its commitment to personalized medicine, particularly in treating central nervous system disorders and cancer. Oryzon boasts a skilled team of professionals based in various locations, including Boston and San Diego, contributing to its robust clinical portfolio.
The company's promising assets include lead candidates like vafidemstat, which is poised for Phase III clinical trials in CNS disorders, and iadademstat, currently in Phase II for oncology applications. Furthermore, Oryzon is advancing another candidate, ORY-4001, targeting HDAC-6 for conditions such as Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis (ALS).
Expert Team and Contact Information
Oryzon’s strength lies in its dynamic team of experts, dedicated to research and development in the biopharmaceutical field. For inquiries or detailed discussions regarding their innovative approaches, Oryzon provides updated contact information for their investor relations and media contacts:
Contact Details
For inquiries within Spain, reach out to Patricia Cobo or Mario Cordera from Atrevia at +34 91 564 07 25 or via email at pcobo@atrevia.com and mcordera@atrevia.com.
For further correspondence, you may also contact Emili Torrell, Chief BD Officer at Oryzon, at +34 93 515 1313 or shoot an email to etorrell@oryzon.com. For specialist media relations in Europe and the US, Sandya von der Weid of LifeSci Advisors can be contacted at +41 78 680 05 38 or svonderweid@lifesciadvisors.com.
Frequently Asked Questions
What events will Oryzon participate in this November?
Oryzon will participate in BIO-EUROPE, LSX Investival Showcase, and the Jefferies Global Healthcare Conference.
Where is BIO-EUROPE being held?
BIO-EUROPE will take place at the Vienna Congress and Convention Center in Austria.
What is Oryzon’s primary focus area?
Oryzon focuses on epigenetics, particularly in personalized medicine for CNS disorders and oncology.
Who can be contacted for more information about Oryzon?
For inquiries, you can contact their representatives via the provided email addresses and phone numbers.
What are Oryzon's significant clinical candidates?
Key clinical candidates include vafidemstat and iadademstat, both of which are advancing through clinical trials.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
